Literature DB >> 21098091

Amelioration of neuropathic pain by novel transient receptor potential vanilloid 1 antagonist AS1928370 in rats without hyperthermic effect.

Tomonari Watabiki1, Tetsuo Kiso, Takahiro Kuramochi, Koichi Yonezawa, Noriko Tsuji, Atsuyuki Kohara, Shuichiro Kakimoto, Toshiaki Aoki, Nobuya Matsuoka.   

Abstract

Transient receptor potential vanilloid 1 (TRPV1) is activated by a variety of stimulations, such as endogenous ligands and low pH, and is believed to play a role in pain transmission. TRPV1 antagonists have been reported to be effective in several animal pain models; however, some compounds induce hyperthermia in animals and humans. We discovered the novel TRPV1 antagonist (R)-N-(1-methyl-2-oxo-1,2,3,4-tetrahydro-7-quinolyl)-2-[(2-methylpyrrolidin-1-yl)methyl]biphenyl-4-carboxamide (AS1928370) in our laboratory. AS1928370 bound to the resiniferatoxin-binding site on TRPV1 and inhibited capsaicin-mediated inward currents with an IC₅₀ value of 32.5 nM. Although AS1928370 inhibited the capsaicin-induced Ca²(+) flux in human and rat TRPV1-expressing cells, the inhibitory effect on proton-induced Ca²(+) flux was extremely small. In addition, AS1928370 showed no inhibitory effects on transient receptor potential vanilloid 4, transient receptor potential ankyrin 1, and transient receptor potential melastatin 8 in concentrations up to 10 μM. AS1928370 improved capsaicin-induced secondary hyperalgesia and mechanical allodynia in an L5/L6 spinal nerve ligation model in rats with respective ED₅₀ values of 0.17 and 0.26 mg/kg p.o. Furthermore, AS1928370 alleviated inflammatory pain in a complete Freund's adjuvant model at 10 mg/kg p.o. AS1928370 had no effect on rectal body temperature up to 10 mg/kg p.o., although a significant hypothermic effect was noted at 30 mg/kg p.o. In addition, AS1928370 showed no significant effect on motor coordination. These results suggest that blockage of the TRPV1 receptor without affecting the proton-mediated TRPV1 activation is a promising approach to treating neuropathic pain because of the potential wide safety margin against hyperthermic effects. As such, compounds such as ASP1928370 may have potential as new analgesic agents for treating neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21098091     DOI: 10.1124/jpet.110.175570

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  27 in total

1.  Depressive behavior in the forced swim test can be induced by TRPV1 receptor activity and is dependent on NMDA receptors.

Authors:  Ramy E Abdelhamid; Katalin J Kovács; Myra G Nunez; Alice A Larson
Journal:  Pharmacol Res       Date:  2013-11-04       Impact factor: 7.658

2.  Carboxyl-terminal domain of transient receptor potential vanilloid 1 contains distinct segments differentially involved in capsaicin- and heat-induced desensitization.

Authors:  John Joseph; Sen Wang; Jongseok Lee; Jin Y Ro; Man-Kyo Chung
Journal:  J Biol Chem       Date:  2013-10-30       Impact factor: 5.157

Review 3.  ThermoTRPs and Pain.

Authors:  Robyn J Laing; Ajay Dhaka
Journal:  Neuroscientist       Date:  2015-01-21       Impact factor: 7.519

Review 4.  Breaking barriers to novel analgesic drug development.

Authors:  Ajay S Yekkirala; David P Roberson; Bruce P Bean; Clifford J Woolf
Journal:  Nat Rev Drug Discov       Date:  2017-06-09       Impact factor: 84.694

Review 5.  Unravelling the mystery of capsaicin: a tool to understand and treat pain.

Authors:  Jessica O'Neill; Christina Brock; Anne Estrup Olesen; Trine Andresen; Matias Nilsson; Anthony H Dickenson
Journal:  Pharmacol Rev       Date:  2012-10       Impact factor: 25.468

6.  Altered pharmacology of native rodent spinal cord TRPV1 after phosphorylation.

Authors:  A J Mogg; C E J Mill; E A Folly; R E Beattie; M J Blanco; J P Beck; L M Broad
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

7.  Forced swim-induced musculoskeletal hyperalgesia is mediated by CRF2 receptors but not by TRPV1 receptors.

Authors:  Ramy E Abdelhamid; Katalin J Kovacs; Jeffrey D Pasley; Myra G Nunez; Alice A Larson
Journal:  Neuropharmacology       Date:  2013-04-25       Impact factor: 5.250

8.  TRPV1-Targeted Drugs in Development for Human Pain Conditions.

Authors:  Mircea Iftinca; Manon Defaye; Christophe Altier
Journal:  Drugs       Date:  2021-01       Impact factor: 9.546

9.  Group III metabotropic glutamate receptors and transient receptor potential vanilloid 1 co-localize and interact on nociceptors.

Authors:  R M Govea; S Zhou; S M Carlton
Journal:  Neuroscience       Date:  2012-05-17       Impact factor: 3.590

Review 10.  TRP channels: potential drug target for neuropathic pain.

Authors:  Lovish Marwaha; Yashika Bansal; Raghunath Singh; Priyanka Saroj; Ranjana Bhandari; Anurag Kuhad
Journal:  Inflammopharmacology       Date:  2016-10-18       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.